Please login to the form below

Not currently logged in
Email:
Password:

Takeda extends its operations

Takeda, Japan's largest pharma company, is to set up sales and marketing operations in Spain, and expand its promotional activities in the Republic of Ireland

Takeda, Japan's largest pharma company, is to set up sales and marketing operations in Spain, and expand its promotional activities in the Republic of Ireland to cover the entire country.

The company now has sales and marketing divisions in eight European countries. In addition to Spain and Ireland, there are wholly-owned subsidiaries in France, UK, Italy, Germany, Austria and Switzerland.

Subsidiary, Takeda Farmacéutica España SA, will start promoting Blopress (candesartan cilexetil), an antihypertensive therapy known as Amias in the UK, and Actos (pioglitazone HCl) one of Takeda's two therapies for Type II diabetes.

In the Republic of Ireland, Takeda expanded promotional activities for Actos in January this year, having been active in a specific part of the country only.

Eric Brunn, CEO of Takeda Pharmaceutical Europe, Takeda's UK subsidiary said: "We are pleased with the expansion of geographical coverage in Spain, one of the most important markets in Europe, and also the nationwide coverage in the Republic of Ireland. We will actively introduce products from our portfolio into these two countries."

In 2004, Takeda received approval for Blopress to be used in the treatment of chronic heart failure (CHF). Candesartan is marketed worldwide as Blopress (or Amias) by Takeda and under the brand name of Atacand by AstraZeneca in more than 70 countries.

30th March 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...
Medopad: the up and coming unicorn transforming remote patient monitoring
Blue Latitude Health speaks to Medopad’s Martha Carruthers to learn how the start-up’s modular apps are helping patients with complex diseases....

Infographics